• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by GENFIT S.A.

    3/10/25 5:10:31 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNFT alert in real time by email
    6-K 1 f6k_031025.htm FORM 6-K

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of report: March 10, 2025

     

    Commission File Number: 001-38844

     

    GENFIT S.A.

    (Translation of registrant’s name into English)

     

    Parc Eurasanté

    885, avenue Eugène Avinée

    59120 Loos, France

     

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F                   ☐ Form 40-F

     

     

     

     

    INCORPORATION BY REFERENCE

     

    The contents of this report on Form 6-K (including Exhibit 99.1) are hereby incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271312) and registration statement on Form S-8 (File No. 333-271311) and related prospectuses, as such registration statements and prospectuses may be amended from time to time, and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Information contained on, or that can be accessed through, any website included in Exhibit 99.1 is expressly not incorporated by reference.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    EXHIBIT LIST

     

    Exhibit

     

    Description

       
    99.1   Press Release dated March 10, 2025.

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      GENFIT S.A.
         
    Date: March 10, 2025 By:   /s/ Pascal PRIGENT
          Name: Pascal PRIGENT
          Title: Chief Executive Officer

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $GNFT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNFT

    DatePrice TargetRatingAnalyst
    12/20/2021$8.00Neutral → Buy
    HC Wainwright & Co.
    9/30/2021$8.00 → $7.00Neutral
    HC Wainwright & Co.
    More analyst ratings

    $GNFT
    SEC Filings

    See more
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/7/25 4:10:07 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/5/25 6:00:48 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      4/29/25 3:10:19 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/24 4:00:25 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by GENFIT S.A.

      SC 13G - Genfit S.A. (0001757064) (Subject)

      5/1/23 4:00:10 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/22 6:28:17 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

      Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic

      5/31/23 4:44:00 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genfit upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00

      12/20/21 6:28:59 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Genfit with a new price target

      HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously

      9/30/21 6:11:01 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Genfit with a new price target

      SVB Leerink reiterated coverage of Genfit with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      4/5/21 6:31:27 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Financials

    Live finance-specific insights

    See more
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care